Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Effects of gustatory stimulants of salivary secretion on the pH and stimulation of saliva of Sjögren’s syndrome patients
ISRCTN ISRCTN39262348
ClinicalTrials.gov identifier
Public title Effects of gustatory stimulants of salivary secretion on the pH and stimulation of saliva of Sjögren’s syndrome patients
Scientific title Effects of gustatory stimulants of salivary secretion on the pH and stimulation of saliva of Sjögren’s syndrome patients: a two arm parallel single centre randomised controlled trial
Acronym N/A
Serial number at source N/A
Study hypothesis Gustatory stimulants of salivary secretion (GSSS) are sold over the counter in wide number of European countries and used to stimulate salivary secretion. The acidic nature of these lozenges suggests that they may increase the risk for dental erosion.

The rationale for this study being to find out if the use of the Dentaid GSSS increases salivary secretion and is safer regarding dental erosion.

The study hypotheses are:
1.There is a significant difference in the salivary pH variation elicited by the new GSSS in patients with Sjögren’s syndrome
2.There is a significant difference in the stimulation of whole saliva secretion capacity elicited by the new GSSS with patients with Sjögren’s syndrome
Lay summary
Ethics approval Ethical Committee at the Faculty of Dentistry of the University of Lisbon and the Portuguese Institute for Rheumathological Diseases approved in December 2009
Study design Two-arm parallel single centre triple-blind randomised controlled trial
Countries of recruitment Portugal
Disease/condition/study domain Primary Sjögren's syndrome
Participants - inclusion criteria 1. Participants (both males and females) above 18 years
2. Suffering from primary Sjögren's syndrome
3. An unstimulated whole saliva flow less than 0.1 mL/min, and a stimulated whole saliva flow greater than 0.2 mL/min
Participants - exclusion criteria 1. Currently taking xerostomic medication
2. Pregnant
Anticipated start date 07/01/2010
Anticipated end date 07/10/2010
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 80
Interventions Salivary buffering capacity will be assessed in all participants at baseline. The participants will randomly be allocated to the control and intervention arms in equal numbers (40 in each arm):
1. Intervention arm: New Gustatory stimulant of salivary secretion - one lozenge of Dentaid® (Dentaid, Spain)
2. Control arm: Traditional, citric acid based gustatory stimulant of salivary secretion - one lozenge of SST® (Sinclair, UK)

Salivary secretion rate and pH changes will be recorded at defined time intervals (minute 0, 1, 2, 3, 5, 8, 10, 15 and 20) to determine the efficacy of saliva stimulation and dental erosion potential of these lozenges.
Primary outcome measure(s) Time of GSSS induced pH drop below 5.5 expressed in minutes as the mean ± 95% confidence interval. In order to better quantify risk differences of GSSS induced pH drop below 5.5 a contingency table compiling the counts of subjects with pH drops below 5.5 for over one minute will be obtained. Additional analyses will be done to calculate association measures like the absolute risk reduction (ARR) and number needed to treat (NNT).
Secondary outcome measure(s) 1. GSSS induced salivary pH variations expressed as the mean ± 95% confidence interval of the three pH measures obtained from salivary samples at defined time points
2. GSSS stimulated salivary flow expressed in ml/min as the mean ± 95% confidence interval of stimulated salivary flow obtained at different time points
3. Overall stimulated salivary flow will also be calculated and expressed in ml/min as the mean ± 95% confidence interval of the total volume of stimulated saliva divided by the total time of each experiment which will be 20 minutes
4. Salivary stimulation output defined as the difference between GSSS and basal salivary flow, expressed as ml/min
Sources of funding Dentaid, S.L. (Spain)
Trial website
Publications
Contact name Prof  Antonio  Mata
  Address Grupo de Investigação em Biologia e Bioquímica Oral
Faculdade de Medicina Dentária da Universidade de Lisboa
Cidade Universitária
  City/town Lisbon
  Zip/Postcode 1649-003
  Country Portugal
  Email admata2@yahoo.com
Sponsor Dentaid, S.L. (Spain)
  Address Oficinas centrales
Ronda Can Fatjó, 10
Parc Tecnologic Del Valles
Cerdanyola
  City/town Barcelona
  Zip/Postcode 08290
  Country Spain
  Email dentaid@dentaid.es
  Sponsor website: http://www.dentaid.com/
Date applied 03/01/2010
Last edited 16/03/2010
Date ISRCTN assigned 16/03/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central